
FIZE Medical, a medical technology company focused on fluid management for critically ill patients, has announced the first close of its Series B financing round.
The round was co-led by Asahi Kasei Medical and Rapha Capital Management, with the company targeting a total financing of $20 million.
Funding to Advance AI-Driven Critical Care
FIZE Medical will use the funding to accelerate development of its FIZE Optima platform, which is designed to use continuous physiological data for AI-driven prediction and treatment guidance.
The company is also using the financing to strengthen its commercial activities in key markets.
Expanding Partnership With Asahi Kasei Medical
The Series B investment expands FIZE Medical’s strategic relationship with Asahi Kasei Medical.
Asahi Kasei Medical launched FIZE kUO® in Japan and currently serves as FIZE Medical’s exclusive distribution partner in the country. Under the expanded partnership, Asahi Kasei Medical will also distribute FIZE kUO® in Europe.
The partnership gives Asahi Kasei Medical a broader role in FIZE Medical’s fluid management technology and critical care strategy.
FIZE kUO® System
FIZE Medical’s FIZE kUO® system provides real-time digital monitoring to support fluid management for critically ill patients.
The system is commercially available in Japan, Europe, and the United States and is designed to support precision fluid management and early intervention.
About FIZE Medical
FIZE Medical is a MedTech company developing technology for fluid management in critical care. The company combines continuous monitoring, clinical evidence, and AI-driven data insights to improve how fluid-related risks are monitored and managed.